139 related articles for article (PubMed ID: 9391500)
1. Mibefradil--a new calcium-channel blocker.
Med Lett Drugs Ther; 1997 Nov; 39(1013):103-5. PubMed ID: 9391500
[No Abstract] [Full Text] [Related]
2. Mibefradil (posicor).
Giles TD
Compr Ther; 1997 Nov; 23(11):761-3. PubMed ID: 9360806
[No Abstract] [Full Text] [Related]
3. Mibefradil, a pharmacologically distinct calcium antagonist.
Ernst ME; Kelly MW
Pharmacotherapy; 1998; 18(3):463-85. PubMed ID: 9620098
[TBL] [Abstract][Full Text] [Related]
4. Mibefradil: a new class of calcium-channel antagonists.
Billups SJ; Carter BL
Ann Pharmacother; 1998 Jun; 32(6):659-71. PubMed ID: 9640486
[TBL] [Abstract][Full Text] [Related]
5. From the Food and Drug Administration.
Nightingale SL
JAMA; 1998 Feb; 279(5):346. PubMed ID: 9459455
[No Abstract] [Full Text] [Related]
6. Steady-state trough plasma mibefradil concentrations and correlation to blood pressure response in hypertensive patients with chronic renal disease.
Pordy R; Woittiez A
Int J Clin Pharmacol Res; 1998; 18(3):105-8. PubMed ID: 9825266
[TBL] [Abstract][Full Text] [Related]
7. The withdrawal of mibefradil (Posicor).
Griffin JP
Adverse Drug React Toxicol Rev; 1998; 17(2-3):59-60. PubMed ID: 9838964
[No Abstract] [Full Text] [Related]
8. [Induction of bradycardia by mibefradil in antihypertensive combination therapy].
Wagner J; Ritz E
Dtsch Med Wochenschr; 1998 Apr; 123(17):547. PubMed ID: 9601479
[No Abstract] [Full Text] [Related]
9. [Mibefradil: a new class calcium inhibitor].
Internist (Berl); 1996 Oct; 37(10 Suppl Mibefradil):1-8. PubMed ID: 9402420
[No Abstract] [Full Text] [Related]
10. Profound symptomatic bradycardia associated with combined mibefradil and beta-blocker therapy.
Rogers R; Prpic R
Med J Aust; 1998 Oct; 169(8):425-7. PubMed ID: 9830391
[TBL] [Abstract][Full Text] [Related]
11. The efficacy and safety of mibefradil in subgroups of patients with chronic stable angina pectoris.
Charlon V; Kobrin I
Int J Clin Pract; 1998 Jun; 52(4):257-64. PubMed ID: 9744152
[TBL] [Abstract][Full Text] [Related]
12. Mibefradil. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the management of hypertension and angina pectoris.
Brogden RN; Markham A
Drugs; 1997 Nov; 54(5):774-93. PubMed ID: 9360062
[TBL] [Abstract][Full Text] [Related]
13. Mibefradil, a T-type channel-selective calcium antagonist: clinical trials in chronic stable angina pectoris.
Massie BM
Am J Hypertens; 1998 Apr; 11(4 Pt 3):95S-102S. PubMed ID: 9607373
[TBL] [Abstract][Full Text] [Related]
14. Safety of mibefradil, a new once-a-day, selective T-type calcium channel antagonist.
Kobrin I; Charlon V; Lindberg E; Pordy R
Am J Cardiol; 1997 Aug; 80(4B):40C-46C. PubMed ID: 9286853
[TBL] [Abstract][Full Text] [Related]
15. Treatment of chronic angina pectoris with combination mibefradil and beta-blocker therapy.
Alpert JS
Clin Cardiol; 1998 Feb; 21(2):129. PubMed ID: 9491954
[No Abstract] [Full Text] [Related]
16. Mibefradil: a new twist to the calcium channel antagonist.
Lynn MM
Nurse Pract; 1998 May; 23(5):100, 102-4, 106-7. PubMed ID: 9614683
[No Abstract] [Full Text] [Related]
17. Mibefradil pharmacokinetic and pharmacodynamic population analysis.
Welker HA; Banken L
Int J Clin Pharmacol Res; 1998; 18(2):63-71. PubMed ID: 9675623
[TBL] [Abstract][Full Text] [Related]
18. Comment: mibefradil, a new class of calcium-channel antagonists.
Otterman S
Ann Pharmacother; 1998 Dec; 32(12):1372. PubMed ID: 9876826
[No Abstract] [Full Text] [Related]
19. [Calcium channel blocker for therapy of patients with hypertension].
Sasaki S; Nakagawa M
Nihon Rinsho; 1997 Aug; 55(8):2061-6. PubMed ID: 9284424
[TBL] [Abstract][Full Text] [Related]
20. Anti-anginal and anti-ischemic effects of mibefradil, a new T-type calcium channel antagonist.
Kobrin I; Bieska G; Charlon V; Lindberg E; Pordy R
Cardiology; 1998; 89 Suppl 1():23-32. PubMed ID: 9570426
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
